Child Health clinical trials at University of California Health
1 research study open to eligible people
Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)
open to eligible people ages 1 month and up
The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings. The proposed trial aims to demonstrate and evaluate large-scale implementation of azithromycin to children aged 1-11 months old in the context of a programmatic setting while monitoring mortality and resistance antimicrobial resistance.
Our lead scientists for Child Health research studies include Tom Lietman, MD.